Animal, fungal and marine sources of cgp and increased cgp concentration for disease management and for treatment of non-neurological and/or neurological conditions

A method of predicting a risk of a non-neurological and/or neurological condition with age in an animal utilising cyclic glycine-proline (cGP) as a plasma biomarker with altered IGF-1 function comprising the steps of:

• a) obtaining a biological specimen from the animal;
• b) measuring a concentration of cyclic glycine-proline (cGP) as a plasma biomarker for active concentration dependent insulin-like growth factor 1 (IGF-1) bioavailability in the biological specimen at a first set age of the animal, or an initial stage of the non-neurological and/or neurological condition, or before treatment of an therapeutically effective amount of a concentrate/extract of cGP derived from animal, marine and/or fungal based material to the animal;
• c) re-measuring the concentration of cyclic glycine-proline (cGP) plasma biomarker for active concentration dependent insulin-like growth factor 1 (IGF-1) bioavailability in the biological specimen at further set age intervals of the animal or further stage of the non-neurological and/or neurological condition, or after treatment of the therapeutically effective amount of the concentrate/extract of cGP derived from animal, marine and/or fungal based material to the animal;
• and
• d) comparing either the measured cGP concentration and/or molar ratio of cGP concentration to total measured amount of IGF-1 in the biological specimen at the set age intervals relative to the first set age, or the initial stage of the non-neurological and/or neurological condition with IGF-1 dysfunction, or before the treatment of the therapeutically effective amount of a concentrate/extract of the cGP derived from animal, marine and/or fungal based material to the animal, in a continuum of results, to confirm whether or not there is a change in the measured cGP concentration and/or molar ratio of cGP concentration to total measured amount of IGF-1 thereby determining whether the animal is at an increased risk of developing a non-neurological and/or neurological condition from cognitive decline relative to a standard set of baseline data, and wherein the above measured ratio is used to select individual patients for cGP treatment and a suitable dosage for the cGP treatment therein.

A method of predicting the spontaneous recovery of an animal with a non-neurological and/or neurological conditions with IGF-1 dysfunction utilising cyclic glycine-proline (cGP) and cGP/IGF-1 molar ratio as the plasma biomarker for IGF-1 function comprising the steps of:

• a) obtaining a biological specimen from the animal;
• b) measuring a concentration of cyclic glycine-proline (cGP) plasma biomarker and active concentration dependent insulin-like growth factor 1 (IGF-1) bioavailability in the biological specimen at a baseline of the animal from onset of the non-neurological and/or neurological condition (<72 h in acute conditions);
• c) re-measuring the concentration of cyclic glycine-proline (cGP) plasma biomarker and active concentration dependent insulin-like growth factor 1 (IGF-1) bioavailability in the biological specimen at further regular intervals of the animal during recovery;
• d) evaluating functional recovery of the animal from the baseline and at further set intervals, and wherein the baseline concentration of CGP from a continuum of data predicts the short term outcome of non-neurological and/or neurological condition recovery of the animal such that a greater baseline cGP concentration, the more positive prognosis for the animal based on the evaluation of functional recovery.

The use of a concentrate/extract of cGP derived from animal, marine and/or fungal based material in the manufacture of a medicament formulated to:

• prevent a decrease in concentration of cGP and/or cGP to total measured IGF-1 molar ratio in an animal;
• and/or
• maintain a pre-existing concentration of cGP and/or cGP to total measured IGF-1 molar ratio in an animal;
• and/or
• increase the concentration of cGP and/or cGP to total measured IGF-1 ratio in an animal.

A concentrate/extract comprising a therapeutically effective amount of cGP derived from animal, marine and/or fungal based material formulated for administration to an animal to:

• prevent a decrease in concentration of cGP and/or cGP to total measured IGF-1 molar ratio in an animal;
• and/or
• maintain a pre-existing (normal/physiological) concentration of cGP and/or cGP to total measured IGF-1 molar ratio in an animal;
• and/or
• increase or to normalise the concentration of cGP and/or cGP to total measured IGF-1 molar ratio in an animal.